The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia.

Treatment with evolocumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with familial homozygous hypercholesterolaemia.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing evolocumab.

Applications

Patients must be treated by or in consultation with a consultant physician. The date of the consultation must be no more than 6 months before the application for a PBS authority.

Initial treatment

Make all initial applications for authority approval to prescribe evolocumab for the treatment of familial homozygous hypercholesterolaemia in writing and: